For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220817:nRSQ2422Wa&default-theme=true
RNS Number : 2422W Arecor Therapeutics PLC 17 August 2022
Arecor Therapeutics plc
("Arecor" or the "Group")
NOTICE OF INTERIM RESULTS
Cambridge, UK, 17 August 2022: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
will announce its Interim Results for the six months ended 30 June 2022 on
Thursday 8 September 2022.
Sarah Howell, Chief Executive Officer, and Susan Lowther, Chief Financial
Officer, will host an in-person briefing for analysts at 11:00am BST on the
day of the results at the offices of Panmure Gordon, One New Change, London,
EC4M 9AF. There will also be a live webcast and conference call with a
Q&A session.
For more details or to attend the briefing, please contact
arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com (http://www.arecor.com/)
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com (mailto:sarah.howell@arecor.com)
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com (mailto:info@arecor.com)
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)
Panmure Gordon (UK) Limited (NOMAD and Broker) Tel: +44 (0) 20 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Gray Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
(http://www.arecor.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NORKQLFFLVLEBBD